Your browser doesn't support javascript.
loading
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette, R; Luger, T; Thaçi, D; Toth, D; Lacombe, A; Xia, S; Mazur, R; Patekar, M; Charef, P; Milutinovic, M; Leonardi, C; Mrowietz, U.
  • Bissonnette R; Innovaderm Research, Montreal, QC, Canada.
  • Luger T; Department of Dermatology, University of Münster, Münster, Germany.
  • Thaçi D; Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Toth D; Department of Geriatric and Environmental Dermatology, Probity Medical Research Windsor and XLR8 Medical Research, Windsor, ON, Canada.
  • Lacombe A; Novartis Pharma AG, Basel, Switzerland.
  • Xia S; Beijing Novartis Pharma Co. Ltd., Shanghai, China.
  • Mazur R; Novartis Pharma AG, Basel, Switzerland.
  • Patekar M; Novartis Pharma AG, Basel, Switzerland.
  • Charef P; Novartis Pharma AG, Basel, Switzerland.
  • Milutinovic M; Novartis Pharma AG, Basel, Switzerland.
  • Leonardi C; Department of Dermatology, Saint Louis University Health Science Center, St Louis, MO, USA.
  • Mrowietz U; Department of Dermatology, Psoriasis-Center, University Medical Center Schleswig-Holstein, Kiel, Germany.
J Eur Acad Dermatol Venereol ; 32(9): 1507-1514, 2018 Sep.
Article en En | MEDLINE | ID: mdl-29444376

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Observational_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Fármacos Dermatológicos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Observational_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2018 Tipo del documento: Article